Piramal Pharma
PPLPHARMANSE

Piramal Pharma

₹205.24-7.43 (3.49%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
202.01
Today’s high
215.85
52 week low
132.30
52 week high
218.50
Open price
203.40
Previous close
212.67
Live volume
1,03,59,456
Lower circuit
170.14
Upper circuit
255.20

Fundamentals

Market Cap
₹28,284Cr
ROE
-3.58%
P/E Ratio(TTM)
--
EPS(TTM)
-2.36
P/B Ratio
3.46
Dividend Yield
0.00%
Industry P/E
37.43
Book Value
61.34
Debt to Equity
0.70
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹2,359
-15.67%
Profit (Cr)
-₹69.39
-685.84%
-40004001.6k3.6k
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+18%
3Y CAGR+8%
Profit growthValue
1Y (TTM)+18%
3Y CAGR-17%

About

Piramal Pharma Limited is a global pharmaceutical company with a presence in over 100 countries. It operates through three main business segments: a) Piramal Pharma Solutions (PPS): An integrated Contract Development and Manufacturing Organization (CDMO). b) Piramal Critical Care (PCC): A complex hospital generics business focusing on inhalation anesthetics and injectables. c) India Consumer Healthcare (ICH): A retail business selling well-known over-the-counter (OTC) brands like Saridon, Lacto Calamine, and i-pill.;
Founded in
2020
NSE symbol
PPLPHARMA

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹23,319.00
+112.00 (0.48%)
L
    H
    29,793.7659.8515.9
    ₹1,563.50
    -7.80 (0.50%)
    L
      H
      18,020.27--3.09
      ₹440.65
      -3.55 (0.80%)
      L
        H
        17,002.63290.464.35
        ₹401.60
        +0.30 (0.07%)
        L
          H
          16,211.3573.423.35
          Livesquawk
          Carlyle's proposed sell-down in Piramal Pharma has been cancelled.
          Livesquawk
          Piramal Pharma Ltd. executed NSE block trade of 1,454,194 shares. Trade valued at Rs. 29.8 crores, priced at Rs. 205.01 per share.
          Livesquawk
          Piramal Pharma restarts Ahmedabad unit operations post flood disruption. Production resumes after flood-related interruption at Ahmedabad units.
          Livesquawk
          Goldman Sachs maintains Buy on Piramal Pharma with a target price of ₹250. Q1 revenue, EBITDA beat estimates, sharp margin expansion, FY27 guidance reaffirmed.
          Livesquawk
          Piramal Pharma expects a normalized tax rate of 24-25% at scale. Tax rate will remain elevated during the current fiscal year, per concall.
          Livesquawk
          Piramal Pharma reaffirmed FY guidance for Complex Hospital Generics, including organic and Kenalog growth. Q1 organic growth rate is unlikely to persist throughout the year, as per concall update.
          2026
          29
          Jul
          Quarterly Result
          Release date
          28
          Apr
          Quarterly & Annual Result
          Release date
          28
          Jan
          Quarterly Result
          Release date
          2025
          5
          Nov
          Quarterly Result
          Release date
          28
          Jul
          Quarterly Result
          Release date

          16
          Jul
          Dividend
          Ex date
          ₹0.14
          per share

          For each share you hold, you will receive ₹0.14
          Dividend amount₹0.14 per share
          Dividend TypeFinal
          Ex Date16 Jul ‘25
          Record Date16 Jul ‘25
          Announcement date14 May ‘25

          14
          May
          Dividend
          Announced
          ₹0.14
          per share

          For each share you hold, you will receive ₹0.14
          Dividend amount₹0.14 per share
          Dividend TypeFinal
          Ex Date16 Jul ‘25
          Record Date16 Jul ‘25
          Announcement date14 May ‘25
          Events calendar
          View upcoming events in other stocks